Advanced

Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease

Nissen, T; Newman, E. J.; Grosset, K. A.; Daghem, M; Pal, G.; Stewart, M.; Odin, Per LU ; Macphee, G. J. and Gosset, D. G. (2012) In Scottish Medical Journal 57(4). p.217-220
Abstract (Swedish)
Abstract in Undetermined

The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this study was to define the length of L-dopa (L-3, 4-dihydrophenylalanine) and dopamine agonist monotherapy. The duration of monotherapy and discontinuation rates were investigated in a natural observational setting by plotting Kaplan-Meier survival curves. Out of 345 patients, 180 (52.2%) received L-dopa and 165 (47.8%) received a dopamine agonist as initial monotherapy. Half of the patients starting L-dopa received supplementary therapy within 3.6 years (95% confidence interval, 3.2-4.6), significantly longer than for dopamine agonist monotherapy... (More)
Abstract in Undetermined

The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this study was to define the length of L-dopa (L-3, 4-dihydrophenylalanine) and dopamine agonist monotherapy. The duration of monotherapy and discontinuation rates were investigated in a natural observational setting by plotting Kaplan-Meier survival curves. Out of 345 patients, 180 (52.2%) received L-dopa and 165 (47.8%) received a dopamine agonist as initial monotherapy. Half of the patients starting L-dopa received supplementary therapy within 3.6 years (95% confidence interval, 3.2-4.6), significantly longer than for dopamine agonist monotherapy (half required a second agent at 2.3 years [2.0-2.9]; P = 0.00017). Discontinuation of L-dopa therapy was 1%. Dopamine agonists were stopped (due to side-effects like impulse control disorders [6%], somnolence [4%] and light-headedness [3%]) in 20% over four years. The duration and tolerability of L-dopa and dopamine agonists as initial Parkinson's disease monotherapy are defined in this study; this may form part of the information exchange with patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
monotherapy, parkinson's disease, discontinuation, dopamine agonists, L-dopa, tolerability
in
Scottish Medical Journal
volume
57
issue
4
pages
217 - 220
publisher
Royal Society of Medicine Press
external identifiers
  • wos:000311926400009
  • scopus:84868689447
ISSN
2045-6441
DOI
10.1258/smj.2012.012121
language
English
LU publication?
yes
id
2a5f3ec3-e398-41fa-aaf6-32d5cef9ecd6 (old id 3288100)
date added to LUP
2012-12-21 14:58:30
date last changed
2017-01-01 04:16:15
@article{2a5f3ec3-e398-41fa-aaf6-32d5cef9ecd6,
  abstract     = {<b>Abstract in Undetermined</b><br/><br>
The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this study was to define the length of L-dopa (L-3, 4-dihydrophenylalanine) and dopamine agonist monotherapy. The duration of monotherapy and discontinuation rates were investigated in a natural observational setting by plotting Kaplan-Meier survival curves. Out of 345 patients, 180 (52.2%) received L-dopa and 165 (47.8%) received a dopamine agonist as initial monotherapy. Half of the patients starting L-dopa received supplementary therapy within 3.6 years (95% confidence interval, 3.2-4.6), significantly longer than for dopamine agonist monotherapy (half required a second agent at 2.3 years [2.0-2.9]; P = 0.00017). Discontinuation of L-dopa therapy was 1%. Dopamine agonists were stopped (due to side-effects like impulse control disorders [6%], somnolence [4%] and light-headedness [3%]) in 20% over four years. The duration and tolerability of L-dopa and dopamine agonists as initial Parkinson's disease monotherapy are defined in this study; this may form part of the information exchange with patients.},
  author       = {Nissen, T and Newman, E. J. and Grosset, K. A. and Daghem, M and Pal, G. and Stewart, M. and Odin, Per and Macphee, G. J. and Gosset, D. G.},
  issn         = {2045-6441},
  keyword      = {monotherapy,parkinson's disease,discontinuation,dopamine agonists,L-dopa,tolerability},
  language     = {eng},
  number       = {4},
  pages        = {217--220},
  publisher    = {Royal Society of Medicine Press},
  series       = {Scottish Medical Journal},
  title        = {Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease},
  url          = {http://dx.doi.org/10.1258/smj.2012.012121},
  volume       = {57},
  year         = {2012},
}